| | Variables | Total () | Subjects with ≥2 identifiable CVD risk factors () |
| | Sex | | | | Male, (%) | 119 (50.4%) | 76 (45.0%) | | Female, (%) | 117 (49.6%) | 93 (55.0%) | | Age at index date, mean (SD) | 55.5 (13.7) | 55.2 (14.1) | | Baseline lab test results | | | | HbA1c, % (SD) | 8.3 (1.4) | 8.2 (1.5) | | Systolic BP, mmHg (SD) | 132.1(15.8) | 134.4(16.4) | | Diastolic BP, mmHg (SD) | 80.0 (11.3) | 81.7 (11.6) | | Total cholesterol, mg/dL (SD) | 158.7 (37.2) | 157.1 (37.5) | | LDL, mg/dL (SD) | 86.5 (30.4) | 89.6 (31.1) | | HDL, mg/dL (SD) | 47.1 (12.1) | 45.0 (11.1) | | Triglyceride, mg/dL (SD) | 171.8 (105.3) | 187.6 (114.5) | | eGFR (MDRP), mL/min/1.73 m2 (SD) | 85.6 (27.0) | 86.8 (26.5) | | eGFR (CKDEPI), mL/min/1.73 m2 (SD) | 88.5 (25.1) | 85.9 (26.5) | | Postprandial glucose, mg/dL (SD) | 158.6 (54.2) | 159.1 (54.6) | | Starting dose | | | | 0.75 mg, (%) | 181 (76.7%) | 129 (76.3%) | | 1.5 mg, (%) | 55 (23.3%) | 40 (23.7%) | | Baseline concomitant antidiabetic medication | | | | Metformin, (%) | 217 (91.9%) | 157 (94.1%) | | Insulin, (%) | 88 (37.3%) | 66 (39.1%) | | Meglitinide, (%) | 1 (0.4%) | 0 (0%) | | DPP4 inhibitor, (%) | 42 (17.8%) | 29 (17.2%) | | SGLT2 inhibitor, (%) | 46 (19.5%) | 33 (19.5%) | | Alpha glucosidase, (%) | 2 (0.8%) | 2 (1.2%) | | Thiazolidinedione, (%) | 9 (3.8%) | 4 (2.4%) | | Sulfonylurea, (%) | 149 (63.1%) | 101 (59.8%) | | DPP4 inhibitor plus metformin combination drug, (%) | 50 (21.2%) | 38 (22.5%) | | SGLT2 inhibitor plus metformin combination drug, (%) | 3 (1.3%) | 2 (1.2%) | | Sulfonylurea plus metformin combination drug, (%) | 6 (2.5%) | 4 (2.4%) | | Pioglitazone plus DPP4 inhibitor combination drug, (%) | 2 (0.8%) | 1 (0.6%) | | Injection history | 134 (56.8%) | 102 (60.4%) | | Previously treated with insulin, (%) | 126 (53.4%) | 96 (56.8%) | | Previously treated with GLP-1RA other than dulaglutide, (%) | 28 (11.9%) | 24 (14.2%) | | Baseline comorbidity | | | | Hypertension, (%) | 89 (37.7%) | 84 (49.7%) | | Obesity, (%) | 21 (8.9%) | 21 (12.4%) | | Dyslipidemia, (%) | 106 (44.9%) | 83 (49.1%) | | Cardiovascular disease, (%) | 29 (12.3%) | 26 (15.4%) | | Kidney disease, (%) | 50 (21.2%) | 38 (22.5%) | | Eye disease, (%) | 72 (30.5%) | 49 (29.0%) | | Neuropathy, (%) | 29 (12.3%) | 20 (11.8%) | | Mental or memory impairment, (%) | 10 (4.2%) | 10 (5.9%) | | Disease history | | | | Previously diagnosed with myocardial infarction, (%) | 12 (5.1%) | 9 (5.3%) | | Previously diagnosed with heart failure, (%) | 4 (1.7%) | 3 (1.8%) | | Previously diagnosed with lesion in thyroid, (%) | 23 (9.7%) | 13 (7.7%) | | CVD risk at baseline | | | | Low (<2 CVD risk factor(s)) | 67 (28.4%) | 0 (100%) | | High (≥2 CVD risk factors) | 169 (71.6%) | 169 (0%) |
|
|
